The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous ...

As part of NASA's SpaceX Crew-11 mission, four crew members from three space agencies will launch in the coming months to the International Space Station for a long-duration science expedition aboard ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

The global axial spondyloarthritis market is set for significant growth, with forecasts indicating a robust CAGR of 14.8% during the period from 2022 to 2028. This growth is primarily attributed to ...

Q: Why did my primary care physician tell me that in order to dodge osteoporosis, which my mom and grandmother have, I need ...

In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel curcumin transdermal formulation developed ...